{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:23Z","timestamp":1761630383510},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.ijantimicag.2005.06.004","type":"journal-article","created":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T10:39:28Z","timestamp":1121769568000},"page":"114-119","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacodynamics of intermittent and continuous infusion piperacillin\/tazobactam and cefepime against extended-spectrum \u03b2-lactamase-producing organisms"],"prefix":"10.1016","volume":"26","author":[{"given":"Alicia M.","family":"Reese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.06.004_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/srin.2002.34693","article-title":"Klebsiella and Enterobacter: antibiotic resistance and treatment implications","volume":"17","author":"Bouza","year":"2002","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1592\/phco.21.11.920.34529","article-title":"Extended-spectrum beta-lactamases: epidemiology, detection, and treatment","volume":"21","author":"Nathisuwan","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archinte.162.2.185","article-title":"Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species","volume":"162","author":"Cosgrove","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/jhin.2002.1286","article-title":"Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) in Northern France: a five-year multicentre incidence study","volume":"52","author":"Albertini","year":"2002","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0732-8893(02)00469-8","article-title":"Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers","volume":"44","author":"Sader","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib7","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin\u2013tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.280.14.1233","article-title":"Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella","volume":"280","author":"Rahal","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib10","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00006454-200008000-00025","article-title":"Limitations of single point pharmacodynamic analysis","volume":"19","author":"Ambrose","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics\u2013pharmacodynamics of cefepime and piperacillin\u2013tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0732-8893(02)00416-9","article-title":"Pharmacodynamic profiling of continuously infused piperacillin\/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis","volume":"44","author":"Kuti","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib15","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.45.12.3468-3473.2001","article-title":"Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis","volume":"45","author":"Montgomery","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib16","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th Informational Supplement M100\u2013S12. Wayne, PA: NCCLS; 2002."},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.36.3.552","article-title":"Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0149-2918(00)87978-3","article-title":"Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion","volume":"22","author":"Burgess","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0149-2918(02)80021-2","article-title":"Pharmacokinetics and pharmacodynamics of piperacillin\/tazobactam when administered by continuous infusion and intermittent dosing","volume":"24","author":"Burgess","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib20","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/AAC.41.11.2511","article-title":"Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin\u2013tazobactam regimens","volume":"41","author":"Occhipinti","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.42.7.1762","article-title":"Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)","volume":"42","author":"Pfaller","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0732-8893(98)00149-7","article-title":"Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group","volume":"33","author":"Pfaller","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1592\/phco.23.12.1232.32706","article-title":"Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period","volume":"23","author":"Burgess","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3201\/eid0702.010238","article-title":"Controversies about extended-spectrum and AmpC beta-lactamases","volume":"7","author":"Thomson","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.47.6.1853-1861.2003","article-title":"Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function","volume":"47","author":"Tam","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.004_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin\u2013tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"Pharmacotherapy"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T22:29:29Z","timestamp":1551911369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0924857905001676"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.06.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}